A Phase 1/?2 Study Of Mrtx0902 In Solid Tumors With Mutations In The Kras Mapk Pathway
Posted Date: Apr 26, 2024
- Investigator: Davendra Sohal
- Specialties: Cancer, Colorectal Cancer, Lung Cancer
- Type of Study: Drug
This is a Phase 1/2, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS-MAPK pathways.
Criteria:
Null
Keywords:
Advanced Solid Tumor, Non Small Cell Lung Cancer
For More Information:
Kayla Webb
NULL
cancer@uchealth.com